Footnote and I grant this is a potentially incendiary comment (heck, the price has been torched so I will feel compelled to whip out my flame-thrower now that the pot has been stirred), however it has not escaped my notice that an entity with much to be gained here as far as triggering events for the DOJ is the FDA itself. The DOJ filing however the chips fall out for NP and Kaz does provide a lot of cover for the FDA. Any sentient Martian dropping in for objective observation could only conclude this was a grievous misstep and embarrassment not to provide an EUA for Leronlimab.

I think it’s a given anything coming out of Vancouver for the FDA from Cytodyn including documents for lifting the hold will be crisp, spell checked, cogent, and above reproach. For this reason I consider lifting of the hold a fait accompli. The hold was after all less about safety and more about lacking integrated safety and risk/benefit analysis…ahem, that was your to-do Amarex.